Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III SPARTAN trial (NCT01946204), a new nonsteroidal antiandrogen (NSAA) treatment, apalutamide, is showing promise in this area. In this exciting interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the encouraging results of this study will impact the treatment and outcomes of patients with nmCRPC. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.
Nonmetastatic CRPC: meeting an unmet need
